Profile data is unavailable for this security.
About the company
United Therapeutics Corporation is a pharmaceutical company. The Company markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection for the treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin. Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder product.
- Revenue in USD (TTM)3.18bn
- Net income in USD1.33bn
- Incorporated1996
- Employees1.40k
- LocationUnited Therapeutics Corp1000 SPRING STSILVER SPRING 20910United StatesUSA
- Phone+1 (301) 608-9292
- Fax+1 (301) 608-9291
- Websitehttps://www.unither.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biomarin Pharmaceutical Inc | 3.22bn | 348.90m | 11.49bn | 3.22k | 33.53 | 1.89 | 26.82 | 3.57 | 1.78 | 1.78 | 16.57 | 31.65 | 0.4418 | 0.4726 | 4.11 | 1,000,079.00 | 4.79 | 3.09 | 5.28 | 3.46 | 81.43 | 78.42 | 10.83 | 8.18 | 3.50 | -- | 0.0893 | 0.00 | 12.87 | 11.60 | -18.26 | 138.08 | -4.20 | -- |
| Jazz Pharmaceuticals PLC | 4.16bn | -368.48m | 11.72bn | 2.80k | -- | 2.92 | 36.90 | 2.82 | -6.07 | -6.07 | 67.81 | 65.18 | 0.3522 | 0.936 | 5.59 | 1,484,940.00 | -3.12 | 1.36 | -3.62 | 1.50 | 88.49 | 88.18 | -8.85 | 3.98 | 1.44 | 2.17 | 0.5752 | 0.00 | 6.12 | 13.48 | 35.02 | 1.37 | -23.40 | -- |
| BridgeBio Pharma Inc | 502.08m | -724.93m | 12.70bn | 834.00 | -- | -- | -- | 25.29 | -3.78 | -3.78 | 2.62 | -10.71 | 0.5412 | -- | 6.97 | 602,009.60 | -79.01 | -76.52 | -105.26 | -96.54 | 95.82 | 96.16 | -145.98 | -340.73 | 2.68 | -2.17 | 4.29 | -- | 126.26 | 127.44 | -35.31 | -- | 4.99 | -- |
| Elanco Animal Health Inc | 4.72bn | -232.00m | 12.97bn | 9.40k | -- | 1.98 | 28.95 | 2.75 | -0.4848 | -0.4848 | 9.53 | 13.17 | 0.3631 | 1.28 | 5.62 | 501,595.80 | -1.79 | -2.26 | -2.01 | -2.53 | 54.99 | 55.59 | -4.92 | -7.41 | 1.08 | 1.15 | 0.3803 | -- | 6.22 | 7.59 | -168.64 | -- | -2.35 | -- |
| Neurocrine Biosciences Inc | 2.86bn | 478.60m | 13.29bn | 2.00k | 28.39 | 4.07 | 26.12 | 4.64 | 4.66 | 4.66 | 27.91 | 32.50 | 0.6851 | 0.8244 | 4.91 | 1,430,250.00 | 11.46 | 9.00 | 13.48 | 10.78 | 98.18 | 98.32 | 16.73 | 13.51 | 3.30 | -- | 0.00 | -- | 21.45 | 22.29 | 40.23 | 3.28 | 25.55 | -- |
| Viatris Inc | 14.30bn | -3.51bn | 18.08bn | 30.00k | -- | 1.23 | -- | 1.26 | -2.96 | -2.96 | 12.22 | 12.78 | 0.3634 | 2.20 | 5.44 | 476,663.30 | -8.93 | -1.35 | -10.68 | -1.61 | 39.55 | 40.86 | -24.58 | -4.18 | 0.8162 | 2.78 | 0.4948 | -- | -2.98 | 3.66 | -454.23 | -- | -7.35 | -- |
| Incyte Corp | 5.14bn | 1.29bn | 19.91bn | 2.84k | 15.62 | 3.84 | 14.43 | 3.87 | 6.40 | 6.40 | 25.61 | 26.04 | 0.8291 | 4.33 | 5.48 | 1,807,750.00 | 20.75 | 11.34 | 27.83 | 14.38 | 93.26 | 93.92 | 25.03 | 16.48 | 3.25 | -- | 0.0067 | 0.00 | 21.22 | 14.03 | 3,844.96 | -- | -20.67 | -- |
| Roivant Sciences Ltd | 13.31m | -809.24m | 20.11bn | 750.00 | -- | 4.67 | -- | 1,510.98 | -1.17 | -1.17 | 0.0193 | 6.02 | 0.0024 | -- | -- | 17,746.67 | -18.26 | 5.89 | -20.80 | 6.98 | 91.21 | 90.39 | -7,558.42 | 639.97 | -- | -- | 0.00 | 0.00 | -11.19 | -15.56 | -111.69 | -- | -1.32 | -- |
| Moderna Inc | 1.94bn | -2.82bn | 20.87bn | 4.70k | -- | 2.41 | -- | 10.74 | -7.26 | -7.26 | 5.00 | 21.95 | 0.1468 | 4.27 | 7.17 | 413,617.00 | -21.31 | 10.19 | -25.32 | 13.43 | 70.32 | 75.74 | -145.16 | 19.02 | 3.22 | -- | 0.0684 | 0.00 | -39.93 | 19.33 | 20.75 | -- | 24.53 | -- |
| United Therapeutics Corp | 3.18bn | 1.33bn | 22.52bn | 1.40k | 18.42 | 3.16 | 15.86 | 7.08 | 27.90 | 27.90 | 66.48 | 162.60 | 0.4176 | 2.25 | 10.11 | 2,273,357.00 | 17.51 | 14.75 | 19.14 | 16.07 | 87.92 | 89.79 | 41.94 | 39.28 | 6.28 | -- | 0.00 | 0.00 | 10.61 | 16.50 | 11.68 | 20.99 | 54.73 | -- |
| Royalty Pharma plc | 2.38bn | 770.95m | 27.38bn | 100.00 | 26.66 | 4.23 | 30.61 | 11.51 | 1.78 | 1.78 | 4.21 | 11.22 | 0.1257 | -- | 84.52 | 23,781,930.00 | 7.00 | 6.72 | 9.03 | 9.10 | -- | -- | 55.68 | 50.56 | -- | 7.06 | 0.4795 | 50.52 | 5.06 | 2.30 | -10.25 | 9.26 | -4.90 | 24.01 |
| Biogen Inc | 9.89bn | 1.29bn | 27.60bn | 7.50k | 21.35 | 1.51 | 13.31 | 2.79 | 8.81 | 8.81 | 67.37 | 124.45 | 0.3441 | 1.04 | 5.30 | 1,318,747.00 | 4.50 | 6.70 | 5.32 | 7.93 | 75.69 | 78.49 | 13.07 | 17.28 | 2.03 | 5.74 | 0.2562 | 0.00 | 2.22 | -5.96 | -20.79 | -20.22 | -19.60 | -- |
Data as of Mar 03 2026. Currency figures normalised to United Therapeutics Corp's reporting currency: US Dollar USD
47.17%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 31 Dec 2025 | 4.14m | 9.61% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 3.85m | 8.95% |
| Avoro Capital Advisor LLCas of 31 Dec 2025 | 2.61m | 6.05% |
| Wellington Management Co. LLPas of 31 Dec 2025 | 2.06m | 4.78% |
| Renaissance Technologies LLCas of 31 Dec 2025 | 1.91m | 4.43% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 1.84m | 4.28% |
| AQR Capital Management LLCas of 31 Dec 2025 | 1.28m | 2.98% |
| Geode Capital Management LLCas of 31 Dec 2025 | 1.19m | 2.77% |
| Janus Henderson Investors US LLCas of 31 Dec 2025 | 793.16k | 1.84% |
| AssetMark, Inc.as of 31 Dec 2025 | 634.96k | 1.48% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
